Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Immunitybio Inc
(NQ:
IBRX
)
3.965
+0.065 (+1.67%)
Streaming Delayed Price
Updated: 2:38 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Immunitybio Inc
< Previous
1
2
3
4
5
Next >
ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
September 09, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
August 12, 2024
From
ImmunityBio, Inc.
Via
Business Wire
NASDAQ:IBRX Long Term Investor Alert: Investigation over Potential Wrongdoing at ImmunityBio, Inc.
November 03, 2023
San Diego, CA -- (SBWIRE) -- 11/03/2023 -- Certain directors of ImmunityBio, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
ImmunityBio Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer
August 06, 2024
From
ImmunityBio, Inc.
Via
Business Wire
IMMUNITYBIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of ImmunityBio, Inc. - IBRX
July 26, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
ImmunityBio Announces Insurance Coverage of ANKTIVA® Across Multiple States with First Commercial Doses Administered Just Weeks After FDA Approval—Opening New Era for Immunotherapy Beyond Checkpoint Inhibitors
June 20, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
June 07, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Connecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
May 17, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®
May 07, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
May 02, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological Association
April 30, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
April 25, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
April 22, 2024
From
ImmunityBio, Inc.
Via
Business Wire
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
Via
FinancialNewsMedia
5 Stocks with Unusually Large Short Interest
March 08, 2024
With the market soaring to new heights, fueled by the tech sector and hype surrounding AI, high short-interest stocks are again under the spotlight.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
March 06, 2024
From
ImmunityBio
Via
Business Wire
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
March 05, 2024
From
ImmunityBio
Via
Business Wire
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
February 21, 2024
From
ImmunityBio
Via
Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
February 14, 2024
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
COVID-19
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
February 05, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
January 02, 2024
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
November 16, 2023
From
ImmunityBio, Inc.
Via
Business Wire
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
November 07, 2023
From
ImmunityBio, Inc.
Via
Business Wire
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
October 26, 2023
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
October 23, 2023
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
September 11, 2023
From
ImmunityBio, Inc.
Via
Business Wire
IBRX DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action – IBRX
August 29, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunityBio, Inc. (IBRX)
August 28, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
NASDAQ:IBRX Investor Notice: Deadline on August 29, 2023 in Lawsuit Against ImmunityBio, Inc.
August 28, 2023
San Diego, CA -- (SBWIRE) -- 08/28/2023 -- The Shareholders Foundation announced that a deadline is coming up on August 29, 2023 in the lawsuit filed for certain investors of ImmunityBio, Inc....
Via
SBWire
Topics
Lawsuit
Exposures
Financial
Legal
IBRX FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX
August 27, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.